NasdaqCM - Delayed Quote USD

Processa Pharmaceuticals, Inc. (PCSA)

1.9600 -0.0400 (-2.00%)
At close: May 17 at 4:00 PM EDT
1.9800 +0.02 (+1.02%)
After hours: May 17 at 4:46 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
10,161.1240
11,457.0610
20,257.2880
11,566.9600
6,436.8590
Operating Income
-10,161.1240
-11,457.0610
-20,257.2880
-11,566.9600
-6,436.8590
Net Non Operating Interest Income Expense
335.2960
335.5410
101.2020
11.6270
-277.9480
Other Income Expense
--
--
-7,268.1430
-402.8120
-8,700.0000
Pretax Income
-9,825.8280
-11,121.5200
-27,424.2290
-11,958.1450
-15,414.8070
Tax Provision
-181.7520
--
--
-530.6110
-1,001.0190
Net Income Common Stockholders
-9,825.8280
-11,121.5200
-27,424.2290
-11,427.5340
-19,039.7360
Diluted NI Available to Com Stockholders
-9,825.8280
-11,121.5200
-27,424.2290
-11,427.5340
-19,039.7360
Basic EPS
-6.06
-8.48
-34.05
-15.00
-50.80
Diluted EPS
-6.06
-8.48
-34.05
-15.00
-50.80
Basic Average Shares
1,643.5600
1,311.5720
805.4770
765.9730
374.9830
Diluted Average Shares
1,643.5600
1,311.5720
805.4770
765.9730
374.9830
Total Operating Income as Reported
-10,161.1240
-11,457.0610
-27,525.4310
-12,133.5430
-15,136.8590
Total Expenses
10,161.1240
11,457.0610
20,257.2880
11,566.9600
6,436.8590
Net Income from Continuing & Discontinued Operation
-9,825.8280
-11,121.5200
-27,424.2290
-11,427.5340
-14,413.7880
Normalized Income
-9,825.8280
-11,121.5200
-20,156.0860
-11,042.6069
-6,278.4180
Interest Income
335.2960
335.5410
101.2020
11.6270
3.1740
Interest Expense
--
--
--
0.3620
281.1220
Net Interest Income
335.2960
335.5410
101.2020
11.6270
-277.9480
EBIT
-10,161.1240
-11,457.0610
-20,257.2880
-11,566.9600
-15,133.6850
EBITDA
-10,160.7630
-11,456.8390
-19,468.7930
-10,775.9880
-14,329.9110
Reconciled Depreciation
0.3610
0.2220
788.4950
790.9720
803.7740
Net Income from Continuing Operation Net Minority Interest
-9,825.8280
-11,121.5200
-27,424.2290
-11,427.5340
-14,413.7880
Total Unusual Items Excluding Goodwill
--
--
-7,268.1430
-402.8120
-8,700.0000
Total Unusual Items
--
--
-7,268.1430
-402.8120
-8,700.0000
Normalized EBITDA
-10,160.7630
-11,456.8390
-12,200.6500
-10,373.1760
-5,629.9110
Tax Rate for Calcs
--
--
--
0.0000
0.0001
Tax Effect of Unusual Items
--
--
--
-17.8849
-564.6300
12/31/2020 - 3/7/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CYCC Cyclacel Pharmaceuticals, Inc.
2.2900
-2.14%
 
PALI Palisade Bio, Inc.
6.36
-1.55%
 
APVO Aptevo Therapeutics Inc.
0.8000
+0.48%
 
PBLA Panbela Therapeutics, Inc.
0.4401
-8.31%
 
ALLR Allarity Therapeutics, Inc.
0.6390
-5.02%
 
SPRC SciSparc Ltd.
1.2200
+1.67%
 
TCBP TC Biopharm (Holdings) Plc
1.1300
-0.88%
 
ZVSA ZyVersa Therapeutics, Inc.
4.4872
-7.67%
 
ADIL Adial Pharmaceuticals, Inc.
1.5500
+9.93%
 
PBM Psyence Biomedical Ltd.
0.8698
-3.03%